Agenus Inc. (Nasdaq: AGEN) will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026. The Lexington, Massachusetts-based immuno-oncology company aims to provide investors with an update on its financial performance and development progress. This reporting date marks a key checkpoint for stakeholders tracking the company’s cash position and operational expenses as it advances its pipeline of immunological agents.

Following the earnings release, Agenus plans to host a webcast later in August to discuss its corporate priorities. Management intends to focus on the acceleration of the botensilimab and balstilimab (BOT+BAL) immunotherapy combination in the neoadjuvant colon cancer setting through the Phase 3 ROBBIN trial. The company will also address upcoming clinical and data milestones and ongoing efforts to support patient access to BOT+BAL. Additional details regarding the webcast agenda and access information will be provided prior to the event.

Pipeline Progress

Agenus is targeting cancer with a comprehensive pipeline of immunological agents, leveraging antibody therapeutics, adoptive cell therapies through MiNK Therapeutics, and adjuvants. Approximately 1,300 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with balstilimab, has shown clinical responses across nine metastatic, late-line cancers.

Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies. Botensilimab augments immune responses by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Balstilimab (BAL) is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

What the Numbers Show

While specific financial metrics for Q2 2026 are not yet disclosed, the timing of this report coincides with significant clinical developments. The emphasis on the Phase 3 ROBBIN trial suggests that capital allocation and burn rate management remain critical as the company transitions from earlier-phase trials to larger-scale studies. Investors will likely scrutinize the balance sheet strength required to fund these late-stage oncology programs without immediate commercial revenue.

Forward-Looking Statements

This press release contains forward-looking statements pursuant to the safe harbor provisions of federal securities laws. These statements include those regarding the botensilimab and balstilimab programs, expected regulatory timelines and filings, and other statements containing words such as "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," "establish," "potential," "superiority," and "best in class." These statements are subject to risks and uncertainties that could cause actual results to differ materially, including factors described under the Risk Factors section of the most recent Annual Report on Form 10-K for 2025 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on these forward-looking statements, which speak only as of the date of this press release.

Agenus Inc. announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer, and advanced sarcoma. The congress is scheduled to take place from October 23 to October 27, 2026, in Madrid, Spain.

The NEOASIS poster will present updated data from a neoadjuvant cohort in mismatch repair-deficient (dMMR) colorectal cancer. This study contributes to the broader clinical rationale for evaluating BOT+BAL before surgery and moving immunotherapy earlier in colon cancer. The two additional posters will present real-world data from investigator-led studies of BOT+BAL in refractory microsatellite-stable/mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer and advanced sarcoma.

Presentation Details

The following table outlines the specific presentations scheduled for the congress:

About BOT+BAL

Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Balstilimab (BAL) is a fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1. Approximately 1,300 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials.